{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:03:34Z","timestamp":1787313814247,"version":"build-2736575974"},"reference-count":135,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Multiple myeloma (MM), the second most common hematologic malignancy in the United States, is characterized by repeated cycles of remission and relapse, with increasing resistance to treatment after each line of therapy. Despite the virtually incurable nature of MM, recent therapeutic breakthroughs have fundamentally reshaped its treatment landscape. This review explores evolving care paradigms, spanning from newly diagnosed MM to relapsed or refractory disease. In the frontline setting, treatment strategies have shifted beyond their traditional emphasis on autologous stem-cell transplant eligibility to a broader categorization of patients on the basis of their suitability for quadruplet therapy. In the relapsed\/refractory setting, novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, have revolutionized treatment, offering new hope for patients with previously limited options. Precision medicine is playing a growing role in MM treatment, with venetoclax showing significant efficacy in patients with t(11;14) translocation, advancing targeted therapy for this subgroup. On the horizon, investigational CAR-T products and cereblon E3 ligase modulators, such as mezigdomide and iberdomide, may provide faster, more durable responses compared with current therapies. In addition, belantamab mafodotin, an antibody-drug conjugate withdrawn from the US market in 2022, is on the verge of reapproval after positive results from recent randomized trials. While these therapies offer significant potential, challenges remain in managing toxicity, ensuring treatment accessibility, and optimizing sequencing strategies. As the therapeutic arsenal expands, the need for personalized MM treatment plans that balance efficacy with quality of life becomes even more essential.<\/jats:p>","DOI":"10.1200\/op-24-00752","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T15:59:12Z","timestamp":1736265552000},"page":"950-961","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":10,"title":["Novel Treatment Options for Multiple Myeloma"],"prefix":"10.1200","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":true,"given":"Andrew J.","family":"Portuguese","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":true,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-7178","authenticated-orcid":true,"given":"GuiZhen","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Reddi","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-7094","authenticated-orcid":true,"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program National Cancer Institute. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405985"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240966"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129431"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00843-5"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180006"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","unstructured":"Usmani SZ Facon T Hungria V et al: OA-63: Daratumumab + bortezomib\/lenalidomide\/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: Results of the phase 3 CEPHEUS study. 21st IMS Annual Meeting 2024 pp S288-S289","DOI":"10.1016\/S2152-2650(24)02344-9"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01034-6"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00937-0"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177546"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01895-0"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0611"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023597"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024371"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163335"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01370"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187233"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad053"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00005-X"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178798"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","unstructured":"Hansen D Peres L Dima D et al: OA-07: A comparison of standard of care idecabtagene vicleucel and ciltacabtagene autoleucel CAR T-cell therapy in relapsed or refractory multiple myeloma. 21st International Myeloma Society Annual Meeting 2024 p S5","DOI":"10.1016\/S2152-2650(24)01848-2"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","unstructured":"Leleu X Chung A Raje N et al: Abstract S208: Idecabtagene vicleucel (ide-cel) in patients (pts) with clinical high-risk early relapse multiple myeloma (MM) without front-line (1L) autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2B. Presented at European Hematology Association Madrid Spain 2024. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/document?c_id=422312&cm_id=437144&type=document437144","DOI":"10.1016\/S2152-2650(24)01948-7"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8"},{"key":"e_1_3_5_38_2","doi-asserted-by":"crossref","unstructured":"Sidana S Patel KK Peres LC et al: Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood 145:85-97 2025","DOI":"10.1182\/blood.2024025945"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01167-8"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012336"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1798"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401530"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178806"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.013"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2352086"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011658"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01107-6"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.002"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_5_56_2","unstructured":"Mohty M Iida S Bahlis NJ et al: Abstract P932: Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MagnetisMM-3. Presented at European Hematology Association Madrid Spain 2024. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/document?c_id=420996&cm_id=435829&type=document435829"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177735"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157547"},{"key":"e_1_3_5_60_2","unstructured":"Banerjee R Chang H Lin D et al: Abstract P992: Teclistamab (tec) step-up dosing (SUD) and treatment dose schedule de-escalation in the real-world (RW) setting: An analysis of multicenter electronic medical records 2024 pp P992. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/document?c_id=421056&cm_id=435889&type=document435889"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7536"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_5_64_2","doi-asserted-by":"crossref","unstructured":"Rasche L Schinke C Touzeau C et al: Abstract P915: Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab a GPRC5DxCD38 bispecific antibody in patients with relapsed\/refractory multiple myeloma 2024 pp P915. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420979\/leo.rasche.long-term.efficacy.and.safety.results.from.the.phase.1.2.html","DOI":"10.1016\/S2152-2650(24)00976-5"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.003"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181228"},{"key":"e_1_3_5_67_2","first-page":"2950","article-title":"Multiple myeloma with t(11;14): Unique biology and evolving landscape","volume":"12","author":"Bal S","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R, et al: Multiple myeloma with t(11;14): Unique biology and evolving landscape. Am J Cancer Res 12:2950-2965, 2022","journal-title":"Am J Cancer Res"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004146"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7510"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180766"},{"key":"e_1_3_5_72_2","unstructured":"Costa A Dhakal B Hultcrantz M et al: OA-58: Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed\/refractory multiple myeloma harboring t(11; 14). 21st International Myeloma Society Annual Meeting 2024 pp S36-S37. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420962\/binod.dhakal.sonrotoclax.plus.dexamethasone.is.tolerable.and.demonstrates.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29201%2Amarker%3D5101%2Afeatured%3D18527"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.08.018"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2874"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.10.071"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0620-8"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01921"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01928"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00290-3"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303194"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2081147"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00476-2"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.57"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008936"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181857"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8005"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116443"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0531"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.992232"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.01.003"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07768.x"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2974"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2341"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0014-2"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00091"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0084"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01774-10"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-165225"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222190"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785659"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128467"},{"key":"e_1_3_5_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2013.12.001"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00365-x"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00461-8"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190612"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166994"},{"key":"e_1_3_5_116_2","unstructured":"Portuguese A: Created in BioRender. https:\/\/BioRender.com\/f80n7002024"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181744"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009507"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27327"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8069"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148463"},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00176-5"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8002"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174941"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.05.008"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017789"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0284-7"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298760"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000308"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01129-0"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.293"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163074"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.018"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-24-00752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:00:36Z","timestamp":1752530436000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-24-00752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":135,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1200\/OP-24-00752"],"URL":"https:\/\/doi.org\/10.1200\/op-24-00752","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}